Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-ICU Trial
NCT07025629Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2025
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in heart failure (HF), chronic kidney disease (CKD), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07025629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025629.